The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb.

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications.The ...

Blood tests for cyclic adenosine monophosphate may be a simple and useful option for diagnosing asthma and determining its ...

Severe eosinophilic asthma (SEA) is rare and affects 40% of SA sufferers. Medicines typically prescribed to treat SA can be ineffective. Treatments including the normal preventer or reliever ...

In his 2025 to 2026 term as American Academy of Allergy, Asthma & Immunology president, Frank S. Virant, MD, FAAAAI, plans to ...

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Gossamer Bio (GOSS – Research Report). The associated price ...

Macleod & MacCallum is sponsoring the Highland Heroes 2025 award for brave child of the year.

Apogee Therapeutics, Inc. (NASDAQ: APGE) has announced the dosing of the first patient in the part B portion of the phase 2 ...